Mehbooba Mufti's daughter wants her mother's name changed in passport
Srinagar: The elder daughter of PDP president Mehbooba Mufti has sought to change her mother's name in her passport to Mehbooba Syed. A notice stating this was published in a local newspaper by Irtiqa Javed.
"I, Irtiqa Javed, daughter of Javed Iqbal Shah Resident of Fairview House Gupkar Road, Srinagar, Kashmir 190001 want to change the name of my mother in my passport from Mehbooba Mufti to Mehbooba Syed.
"If anybody has any objection regarding the same may please contact the concerned authorities within the period of seven days after that no objections will be entertained," the notice read.
The change in the name, according to close aides, was necessitated because Irtiqa's matriculation certificate had her mother's name as Mehbooba Syed.
Mehbooba Mufti and Shah have two daughters -- Irtiqa and Iltija. Mehbooba is under detention at her official residence here that has been declared as a subsidiary jail.
She was among the hundreds of people who were taken into preventive custody hours ahead of the Centre revoking the special status of Jammu and Kashmir and breaking the state into two union territories on August 5 last year.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Ballari maternal deaths: Karnataka govt. seeks explanation from CDSCO
Bengaluru: The Karnataka Government has sought clarification from the Central drugs standard control organisation following reports linking the serial deaths of pregnant women at Ballari District Hospital to unsafe IV Ringer's Lactate solution. Health Department Principal Secretary Harsha Gupta has written a letter to the Drugs Controller General of India, Rajeev Singh Raghuvanshi.
Recent Investigations revealed bacterial and fungal contaminants in the IV solution given to the women. Out of 192 batches supplied by a West Bengal-based pharmaceutical company, 22 were found substandard by the state drug control department, leading to the suspension of the medicine's use.
However, these batches had passed quality tests at the Central Drug Lab, creating a regulatory conflict.
The Health Department emphasized adherence to tender rules, stating that the Central Drug Lab's approval is legally binding. Samples from the problematic batches have been sent for re-testing at the central lab in West Bengal, with results expected on December 9.
As a precautionary measure, the state has blacklisted the implicated batches and issued directives to halt their use in all hospitals.
